Lisa Lallos Email & Phone Number

Chelmsford, Ma, Us

Cary, Nc, Us

Develops strategic plans, manages CR/MO-client relationships and their budgets, maintains project timelines and budgets, and writes/submits SBIR/STTR grant applications for biological therapeutics and vaccines, small molecule compounds, and nanoparticle/liposome treatments for oncology, wound treatment, schizophrenia as well as several orphan indications.

Fairfield, New Jersey, Us

Fairfield, New Jersey, Us

• 2012 Chapter Excellence Award• Lead 15 member committee• Establish yearly strategic plan • Propose and coordinate four events per year

• Formulated recommendations and represented biology group in a cross-functional, CEO- sponsored corporate strategic planning initiative.• Managed biology group IND submission process for lead protease inhibitor compound. • Created cross-departmental lead compound prioritization process that established a target product profile with go/no go gates.• Increased RT-qPCR assay efficiency and accuracy by 67% and decreased costs by 61% in support of its expanded use in the company’s drug discovery process.• Developed a transient transfection assay for resistance characterization of lead compounds, including generating over 15 mutant HCV replicon constructs.• Created six new reagents in 1.5 months for resistance characterization of lead HCV compounds.• Directed research activities of biology group for generating and characterizing HCV drug resistance to a lead protease inhibitor compound (IDX320) in genotype 1a and 1b replicon models. IDX320-resistant mutations were identified, characterized, and orally presented at an international conference. • Developed and directed innovative studies to support the company’s position on the benefit of combination therapy from different antiviral classes for the treatment of HCV.• Managed career development and achievements of a research associate, resulting in accelerated promotion and special recognition awards.

• Author and principal investigator for 2 Small Business Innovation Research (SBIR) grants, totaling $900,000 in new research funds, for the discovery of antiviral compounds to HIV or influenza from marine microorganisms.• Principal investigator for smallpox antiviral discovery SBIR grant.• Designed, executed, and interpreted experiments for antiviral, vaccine, and virus inactivation projects involving HIV, influenza, smallpox, and parvovirus. • Directed cross-functional teams (microbiology, virology, engineering, chemistry) for successful completion of SBIR projects. • Established proof-of-concept for using supercritical fluid technology to physically inactivate HIV.• Developed assays for screening and confirming screening hits from proprietary natural product library.• Led efforts of research associates.

Cambridge, Massachusetts, Us

Developed and evaluated proprietary methodology designed to target an HIV DNA vaccine to Fc receptor-bearing cells in mice. Developed expertise in:• Cellular immunity techniques including CTL, T helper cell, and tetramer staining assays• Large-scale purification of DNA vaccines

Ph.D., Immunology

M.S., Immunology

B.S., Biology